Background. Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation. Here, we investigated how anaemia, ESA resistance and the plasma levels of biological markers of inflammation could influence all-cause and cardiovascular disease morbidity and mortality. Methods. Seven hundred and fifty-three haemodialysis (HD) patients (mean age 66 6 14.2 years, mean dialytic age 70 6 77 months and diabetes 18.8%) were enrolled and followed-up for 36 months. Demographic, clinical and laboratory data, co-morbidity conditions, administered drugs, all-cause mortality and fatal/non-fatal cardiovascular (CV) events were recorded. We measured ESA /INS> resistance index, C-reactive protein (CRP) and interleukin-6 (IL-6). Results. Six hundred and fifty-one patients (86.4%) received ESAs. Patients with haemoglobin level <11 g/dL (n ¼ 225) showed increased risk of CV [relative risk (RR) 1.415, 95% confidence interval (CI) 1.046-1.914] and overall mortality (RR 1.897, 95% CI 1.423-2.530) versus patients with haemoglobin levels >11 g/dL. ESA resistance values categorized into quartiles (Quartile I <5.6, Quartile II 5.7-9.6, Quartile III 9.7-15.4 and Quartile IV >15.4) correlated with all-cause mortality and fatal/ non-fatal CV events (RR 1.97, 95% CI 1.392-2.786; RR 1.619, 95% CI 1.123-2.332, respectively). Furthermore, albumin was significantly reduced versus reference patients and correlated with all-cause mortality and CV events; CRP levels were higher in hyporesponders (Quartile IV) (P < 0.001) and predicted all-cause mortality and CV events. IL-6 but not CRP was a strong predictor of ESA resistance. Conclusions. ESA responsiveness can be considered a strong prognostic factor in HD patients and seems to be tightly related to protein-energy wasting and inflammation.
Introduction
Anaemia is a common complication and predictor of mortality in haemodialysis (HD) patients [1] [2] [3] . A vast majority of patients with chronic kidney disease (CKD) receive erythropoiesis-stimulating agents (ESAs) [4] and resistance to this therapy is common [5] . In HD patients, anaemia is linked to inflammation and oxidant stress is associated to the uraemic syndrome [6] . Moreover, CKD patients may require much higher than usual doses of ESAs in order to maintain the recommended haemoglobin target of !11 g/dL [7] [8] [9] . In many instances, these patients will have either an obvious or a clinically unapparent inflammatory process to account for the hyporesponsiveness to ESAs replacement therapy [10, 11] . In this setting, the term 'ESAs resistance' has been introduced to define patients who fail to reach the target despite a higher than usual dose of ESAs or who continuously need these higher dose in order to maintain it.
A prospective observational study (RISCAVID, 'RISchio CArdiovascolare nei pazienti afferenti all'Area Vasta In Dialisi') was performed on a large HD population in the north-western area of Tuscany, Italy, during a follow-up time of 36 months and part of the results were previously published [12] .
In the present study, we searched the RISCAVID database to investigate how anaemia, ESAs resistance and the plasma levels of biological markers of chronic inflammation could influence all-cause mortality and fatal/non-fatal cardiovascular (CV) events.
Materials and methods

Protocol
The protocol complied with the ethical guidelines of the Declaration of Helsinki and informed consent was obtained from each patient. The study was registered in the Cochrane Renal Group registry for 'Cardiovascular risk in dialysis: RISCAVID study' (#CRG040700112). Analysis on anaemia and anaemia management were pre-specified in the study protocol. All parameters were performed during a midweek dialysis day.
Study cohort and data collection
Starting from June 2004, all prevalent patients in HD afferent to a dialysis centre in the north-west area of Tuscany were considered eligible for the study (n ¼ 757). Patients were enrolled in the study after being on HD for at least 90 days. Of the 757 patients, 4 were not considered in the current analysis due to missing data in anaemia management.
At study enrolment, demographic characteristics, CKD and medical history, dialysis and medication prescriptions and laboratory data were recorded. Diabetes was defined by the use of insulin or oral hypoglycaemic agents. Hypertension was defined as use of medication or blood pressure >130/85 mmHg. We chose one-time point of haemoglobin and ESA in patients who had been stable for the last 3 months.
At follow-up, the occurrence of fatal events were recorded at 6-month intervals from June 2004 until June 2007 by five nephrologists of the RISCAVID study group, who periodically visited each centre. Death events were classified as due to cardiovascular disease (CVD), i.e. myocardial infarction, congestive heart failure, stroke, sudden death or to non-CVD (infection, malignancy and unknown causes). During follow-up visits, dialysis and medication prescription were also recorded.
Laboratory measurements
Blood sampling was performed at the start of the study in a midweek dialysis day. All serum parameters were measured using standard, provincially accredited laboratory techniques. Serum albumin, C-reactive protein (CRP) and interleukin-6 (IL-6) were centrally determined at the Immunopathology Laboratory of the Internal Medicine Department, University of Pisa. Single-point measurements of CRP and IL-6 were made at the beginning of the study. Samples were taken into chilled ethylenediaminetetraacetic acid vacutainers placed immediately on ice and centrifuged within 30 min at À4°C. Plasma was stored at À80°C before assay. Serum albumin was measured with a nephelometric technique (Dade Behring GmbH, Marburg, Germany). IL-6 (Biosource, Camarillo, CA) was measured by quantitative sandwich enzyme immunoassay techniques. Plasma, collected using heparin as anticoagulant, was separated <30 min after drawing and stored at À80°C until analysis. Samples were assayed in duplicate and the intra-and inter-assay coefficient of variation for IL-6 was <5.3 and 7.2%, respectively. The limit detection of IL-6 was <5 pg/mL.
ESAs resistance
In order to normalize the amount of ESAs required depending on the severity of anaemia, we calculated an ESAs resistance index (ERI) defined as the weekly ESAs dose per kilograms of body weight divided by haemoglobin level (grams per decilitre). ERI was calculated only at the start of the study. On the basis of the ERI values, patients were divided into four quartiles; patients belonging to Quartile IV were defined as hyporesponders. A ratio of 1:200 was used to convert darbepoetin alpha to the ESAs equivalent dose (1 lg of darbepoetin alpha ¼ 200 IU of epoetin alpha or beta).
HD modalities
Data on HD modality, including the type of HD and Kt/V, were collected from all HD patients. Standard low-or high-flux bicarbonate HD was performed using either synthetic low-flux polysulphone membrane (from 1.4 to 1. 
Statistical analysis
Chi-square test and Student's t-test or Mann-Whitney test were used to compare proportions and means, respectively. Correlations were reported as either the Pearson correlation coefficient or the Spearman rank correlation coefficient. The cumulative probability of survival from the entry in the study (defined as the time of June 2004) to the terminal event (stated as all-cause mortality or CV events) was estimated by the Cox analysis method. A Cox's proportional hazard model with all-cause mortality, CV mortality and major non-fatal CV events as outcome was used to jointly test the effect of predictors of survival times adjusted for several demographic, clinical and biochemical parameter ( Table 3 ). The backward elimination was used in identifying the most important prognostic factors. Cox's proportional hazard model was also used to compute multivariateadjusted relative risk (RR) estimates and 95% confidence intervals (CI). In the Cox's model, computations were performed on log-transformed values of quantitative variables. The independent prognostic power for all-cause and CV mortality of each inflammation marker was calculated. Briefly, to construct a basic multivariate Cox models for all-cause mortality and major fatal/non-fatal CV events, we preliminarily identified a set of variables that were associated (with P < 0.10) to these outcomes at univariate COX regression analysis (Table 2) . These variables were then used to construct two basic models: the first for all-cause mortality and the second for major non-fatal CV events and CV mortality. In both models, we alternatively included haemoglobin or ERI as predictor variables. Hazard ratios and their 95% CIs were calculated with the use of the estimated regression coefficients and their standard errors in the Cox regression analysis. Multinomial logistic regression analysis was used to investigate the association between risk of a patient belonging to hyporesponders group and explanatory variables. In the multinomial logistic regression analysis, some explanatory variables were recorded to binary variables. All calculations were made using a standard statistical package (SPSS for Windows Version 13.0, Chicago IL, 1 September 2004). All tests were considered significant with P < 0.05.
Results
Study cohort and follow-up Table 1 summarizes the demographic, clinical, laboratory characteristics and HD modalities of the study population (as categorical and continuous variables). Only 29.2% of the patients had levels of haemoglobin according to the National Kidney Foundation-K/DOQI guidelines [8] . Values <11 g/dL were recorded in 29.7%, while 41.1% of the patients had values >12 g/dL. The type of ESAs varied among centres: 45% of the patients were treated with epoietin alpha intravenously (i.v.), 17% with epoietin beta subcutaneously (s.c.), 12% with darbepoietin i.v., 6% with darbepoietin s.c. and 6% with epoietin beta i.v. Of relevance, 14% of patients were not treated at all with ESAs and were adopted as reference group. Plasma levels of inflammatory markers were as follows: for CRP, 10 AE 14.5 mg/L and for IL-6, 8.7 AE 14 pg/mL. During the study follow-up (36 months), 207 of the 753 HD patients died and 208 experienced a fatal/non-fatal CV event.
Impact of anaemia and ESAs resistance in all-cause mortality and fatal/non-fatal CV events
The clinical and biochemical parameters affecting allcause mortality and fatal/non-fatal CV events by the univariate Cox analysis are summarized in Table 2 . Of note, the predictive power of ERI both as continuous and categorical variable for fatal/non-fatal CV events appeared to be higher than haemoglobin. By categorizing patients on the basis of three haemoglobin intervals (<11, 11-12, >12 g/dL), the Cox multivariate analysis showed that haemoglobin levels <11 g/dL were associated with the highest risk for all-cause mortality, while patients with haemoglobin levels >11 g/dL had the lowest mortality risk, which was comparable to the reference group (no ESAs) (Figure 1 ). The other independent predictors of all-cause mortality in the multivariate Cox regression analysis were age (years), albumin (grams per decilitre), CVD (no versus yes) and CRP (milligrams per litre) ( Table 3 ). The impact of haemoglobin levels, as continuous or categorical variable, on fatal and non-fatal CV events was not statistically significant. In our model, the independent predictors of CV events were age, history of CVD and total serum cholesterol (Table 3 ).
In order to investigate the degree of responsiveness to ESAs, we adopted the ERI (see Subjects and methods). In the Cox analysis, for all-cause mortality and fatal/non-fatal CV events, the predictive power of ERI was higher than that of haemoglobin as continuous or categorical variables on the basis of the loss of chi-square attributed to removing each component. Multivariate Cox regression analysis including the 75th percentile of ERI as categorical variable suggested a highly significant correlation with all-cause mortality and fatal/non-fatal CV events. In particular, patients with high ERI (>75th percentile) showed an increase of all-cause mortality (63%) and fatal/non-fatal CV events (43%) ( Table 3 ) (Figure 2A and B) .
Factors modulating ERI
In Table 4 , the categorical and continuous variables were analysed according to ERI values categorized into four quartiles (corresponding ERI values: Quartile I <5.6, Quartile II 5.7-9.6, Quartile III 9.7-15.4 and Quartile IV >15.4). Patients belonging to Quartile IV were predominantly males, oldest and with the lowest serum albumin and transferrin saturation (TSAT) values as well as the highest plasma IL-6 levels. It was interesting to note that only 14.6% of Quartile IV patients were on Sevelamer versus 29.1% of Quartile I patients. There was not significant correlation between Sevelamer and plasma levels of CRP and IL-6 (data not shown). Factors modulating ERI by multinomila logistic regression (Table 5) .
Serum albumin, plasma IL-6, TSAT, acetilsalicil acid (ASA) therapy and therapy with Sevelamer could predict ERI in the Quartile IV by multinomial logistic regression. More specifically, these factors showed a different weight in predicting the RR, increase of allocation to Quartile IV. Serum albumin (140% for every 1.0 g/dL reduction), TSAT (1.5% for every 1.0% saturation reduction) and plasma IL-6 (2% for every 1 pg/mL higher). The therapy with Sevelamer could reduce the risk up to 2.6-fold and the therapy with ASA up Table 3 . Independent predictors of all-cause mortality and fatal/non-fatal CV events in the multivariate Cox regression analysis including Hb (<11 versus !11 g/dL) (a) or ERI IV quartile (b) as predictors in the model; HR, hazard ratio to 1.5-fold. We found no difference in patients with or without therapy with Sevelamer, ASA or statins versus IL-6 and CRP values (P > 0.05).
Discussion
The results of our study can be summarized as follows. Firstly, haemoglobin levels <11 g/dL were associated with the highest risk for all-cause mortality and fatal/non-fatal CV events, while patients with haemoglobin levels >11 g/dL had the lowest all-cause mortality risk which was comparable to the reference group (no ESAs). After adjusting for confounders, haemoglobin did not affect fatal/non-fatal CV events. Other factors such as age, history of CVD, and serum albumin influenced both all-cause mortality and fatal/non-fatal CV events; CRP was a predictor of all-cause mortality but not of fatal/non-fatal CV events; conversely, total cholesterol predicted fatal/non-fatal CV events but not all-cause mortality (Table 3) . Of note, Kt/V, pre-HD blood urea, HD versus HDF, smoking and pulse pressure increased the RR of all-cause mortality and/or of fatal/nonfatal CV events at the univariate but not at the multivariate analysis (Table 2) . Moreover, CRP and IL-6 did not increase the RR of fatal/non-fatal CV events. Furthermore, ERI showed a highly significant correlation with all-cause and CV mortality. In our model, the predictive power of ERI was higher than that of haemoglobin. Moreover, hyporesponders were the oldest and with the lowest serum albumin and TSAT as well as the highest plasma IL-6 values. However, serum albumin is not a valid marker of protein-energy wasting given its dependence on inflammation, urinary albumin losses and hydration status. Finally, factors that influenced ERI were low serum albumin, IL-6, as well as TSAT and therapy with Sevelamer, statins and ASA. Of note, CRP did not influence ERI. Although the study is confirmatory, the results are based on a rather large cohort of a rather homogeneous HD population. The prognostic significance of ESA resistance has been studied before by Kilpatrick et al. [13] , who showed that a greater responsiveness to ESAs is associated with improved survival. As shown by the secondary analysis of the CHOIR Trial [14] , patients achieving their haemoglobin target had better outcomes than those who did not. Therefore, the evaluation of the mechanisms interfering with the action of ESA seems relevant for the determination of appropriate anaemia management.
As reviewed by Stenvinkel and Bárány [6] , there is consensus on a link between CKD and inflammation. A number of studies have highlighted the association between increased inflammatory indexes and a reduced response to ESAs, in particular, high CRP levels were found in HD patients requiring higher ESA doses [15, 16] . However, our results do not confirm the association between ESA resistance and increased CRP levels previously found in other studies [17, 18] . We showed that plasma IL-6 rather than CRP better predicts outcomes in CKD patients [19] . Monocytic IL-6 and tumour necrosis factor-a (TNF-a) levels were directly correlated with an increased ESAs requirement in HD patients [20, 21] . Of interest, it is apparent that chronic inflammation may induce an enhanced state of T-cell activation, and indeed, it has been shown that T cells from poor responders to erythropoietin are in an enhanced activation state (Cooper et al.) . In the absence of any other cause (such as iron deficiency), the overproduction of erythropoiesis-inhibiting cytokines (interferon-c, TNF-a, IL-10 and IL-13) may account for hyporesponsiveness to erythropoietic therapy in patients with CKD [21] .
Various possible explanations may underline the advantage of IL-6 over CRP as a predictor of ESAs resistance. One possibility is that IL-6, being located upstream in the cascade of events, which lead to the synthesis of many acute-phase reactants, is a better marker for the inflammatory burden affecting the development of CVD. Our present study extends the notion that in a large population IL-6, but not CRP, was a strong independent predictor of ESA resistance. Finally, as suggested by Girndt et al. [22] , a genetic polymorphism of IL-6 (-174G/C) might have occurred in our population that could directly inhibit haematopoiesis.
Future studies will have to address whether other as yet unravelled inflammatory mediators may synergistically or additively increase the power of prediction for ESAs resistance [23] . Finally, among other factors influencing ERI was the therapy of Sevelamer and ASA most probably in relation to their anti-inflammatory effect [24, 25] .
Our study has some important limitations. Firstly, despite the fact that we enrolled stable patients, we chose a single time point of haemoglobin measurement when there is considerable haemoglobin variability. The sharp fall in survival at 12 months and to a lesser extent at 18 and 24 months clearly indicates inconsistent reporting of events in the study, with 'peak' capture at 6-monthly intervals. Our study also evaluated IL-6 and CRP with a single-point measurement and correlated these continuous variables with the end points in accordance to the study design by Yeun et al. [26] . Furthermore, this was not a randomized trial and potential confounders might have influenced our results. The applicability of our results to other HD populations remains uncertain since this study reflects the 'state of the art' in HD units and the prognostic significance of ESAs resistance in a population relatively homogeneous for race, geography, medical care and HD management.
In conclusion, ESAs resistance was inversely correlated to haemoglobin and was a strong predictor of all-cause and fatal/ non-fatal CV events. While CRP was confirmed as a strong predictor of all-cause mortality, it has no predictive power for ESAs resistance. In this study, however, IL-6 proved to be a strong independent predictor of ESAs resistance. All factors and covariates with P < 0.05 displayed in Table 4 were included in the model but only significant predictors are reported in the table. HR, hazard ratio.
